Lexicon Pharmaceuticals, INC Form 4 insider transactions

Judith L. Swain, a Director at Lexicon Pharmaceuticals, Inc., reported the acquisition of 89,312 shares of common stock on June 3, 2026, through the vesting of restricted stock units.

Lexicon Pharmaceuticals Director Diane E. Sullivan acquired 89,312 shares of common stock through the vesting of restricted stock units.

Lexicon Pharmaceuticals Director Christopher J. Sobecki acquired 89,312 shares of common stock through the vesting of restricted stock units.

Ivan Cheung, a Director at Lexicon Pharmaceuticals, reported the acquisition of 89,312 shares of common stock upon the vesting of restricted stock units.

Lexicon Pharmaceuticals Director Sam L. Barker acquired 89,312 shares of common stock through the vesting of restricted stock units.

Lexicon Pharmaceuticals Director Philippe Amouyal reported the acquisition of 89,312 shares of common stock.

Director Raymond Debbane of Lexicon Pharmaceuticals, Inc. reported the acquisition of 89,312 shares of common stock on June 3, 2026, through restricted stock units.

Major shareholder Artal Participations converted over 400,000 preferred shares into 20.4 million common shares of Lexicon Pharmaceuticals following shareholder approval.

Lexicon Pharmaceuticals Director Philippe Amouyal reports transactions involving restricted stock units and stock options.

Lexicon Pharmaceuticals Director Christopher J. Sobecki reported transactions involving restricted stock units and stock options on May 1, 2026.

Director Sam L. Barker of Lexicon Pharmaceuticals, Inc. reported transactions involving restricted stock units and stock options on May 1, 2026.

Judith L. Swain, a Director at Lexicon Pharmaceuticals, Inc., reported the acquisition of stock options and restricted stock units on May 1, 2026.

Lexicon Pharmaceuticals Director Diane E. Sullivan reported transactions involving restricted stock units and stock options.

Director Raymond Debbane of Lexicon Pharmaceuticals, Inc. reported transactions involving restricted stock units and stock options.

Wendy McDermott, SVP of Human Resources at Lexicon Pharmaceuticals, reported the exercise of restricted stock units and subsequent sale of shares to cover tax obligations.

Lexicon Pharmaceuticals SVP Rachel Martens converted restricted stock units into common stock and sold a portion to cover tax obligations.

Lexicon Pharmaceuticals' SVP and Chief Medical Officer, Craig B. Granowitz, reported the conversion of restricted stock units into common stock and a subsequent sale to cover tax obligations.

Lexicon Pharmaceuticals' SVP of Discovery, Suma Gopinathan, increased her direct beneficial ownership by exercising restricted stock units and selling shares for tax obligations.

Lexicon Pharmaceuticals' SVP of Investor Relations and Corporate Communications, Lisa DeFrancesco, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

Lexicon Pharmaceuticals' SVP, General Counsel & Secretary, Brian T. Crum, converted restricted stock units into common stock and subsequently sold shares to cover tax obligations.

Lexicon Pharmaceuticals' SVP and CFO, Scott M. Coiante, exercised restricted stock units and subsequently sold a portion of the resulting common stock to cover tax obligations.

Lexicon Pharmaceuticals CEO Michael Exton converted restricted stock units into common stock and simultaneously disposed of shares to cover tax obligations.

Lexicon Pharmaceuticals Director Raymond Debbane purchased 2,000 shares of common stock, signaling confidence in the company.

Lexicon Pharmaceuticals Director Raymond Debbane filed a Form 4 indicating a future acquisition of 100,000 common shares at $1.47 via a Rule 10b5-1 plan.

Lexicon Pharmaceuticals Director Raymond Debbane acquired 150,000 shares of common stock for approximately $219,000 through open market purchases.

Artal Participations S.a r.l., a 10% owner and director, acquired over 41,000 shares of Lexicon Pharmaceuticals Series B Convertible Preferred Stock for $2.68 million.

Key insiders, including Artal Participations and Invus entities, significantly increased their beneficial ownership in Lexicon Pharmaceuticals through recent stock purchases and a preferred stock agreement.

Lexicon Pharmaceuticals, Inc. Director Judith L. Swain was granted 103,806 stock options and 89,312 restricted stock units on June 3, 2025, as detailed in a recent SEC Form 4 filing.

Diane E. Sullivan, a Director at Lexicon Pharmaceuticals, Inc., was granted 103,806 stock options and 89,312 restricted stock units on June 3, 2025, as part of her compensation.

Lexicon Pharmaceuticals, Inc. Director Christopher J. Sobecki was granted 103,806 stock options and 89,312 restricted stock units on June 3, 2025, as reported in a recent SEC Form 4 filing.